Key Finding:
Sarcoma subtypes previously demonstrated as immune checkpoint inhibitor responsive have high T cell inflamed score (TIS), suggesting other sarcomas with high TIS may be responsive as well.
Key Finding:
Sarcoma subtypes previously demonstrated as immune checkpoint inhibitor responsive have high T cell inflamed score (TIS), suggesting other sarcomas with high TIS may be responsive as well.
– Caris Life Sciences
Introduction: Sarcomas are rare, heterogeneous tumors Predictive biomarkers may help direct the optimal selection of therapy Identification of new therapeutic targets is needed Methods: Multiplatform… […]
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |